EDC for real-world data studies: RWD collection, eConsent, ePRO, and 21 CFR Part 11–aligned controls for analysis and regulatory use.
21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required
Real-world data comes from diverse sources, each with its own collection methodology and quality considerations. Electronic health records (EHRs) contain clinical notes, lab results, medication records, and diagnosis codes that can be abstracted into structured CRFs. Claims databases provide information on healthcare utilization and costs. Patient-reported data captures the participant perspective on symptoms, functioning, and quality of life. And digital health devices (wearables, connected monitors) generate continuous physiological data. Capture is designed to serve as the structured data collection layer for RWD studies, regardless of the underlying data source. For EHR-derived data, coordinators or data abstractors enter information from source documents into structured CRFs, with the audit trail recording who entered the data, when, and from what source. For patient-reported data, ePRO questionnaires are completed directly by participants on their own devices. For clinician-assessed data collected during routine care visits, site staff enter observations and assessments into visit-based CRFs. By routing all RWD through a single structured data capture system, study teams create a unified, auditable dataset that is ready for analysis. This is a significant advantage over approaches that attempt to combine data from multiple uncontrolled sources, where data quality, formatting, and provenance documentation vary unpredictably.
Data governance is the foundation of credible real-world evidence. When RWD is used to support regulatory decisions, HTA submissions, or publication in peer-reviewed journals, reviewers evaluate not just the analysis but the entire data lifecycle: how data was collected, who had access, what quality controls were applied, and whether the dataset is reproducible from source. An RWD study with weak data governance—even if methodologically sound—will face skepticism from these audiences. Capture provides the data governance infrastructure that RWD studies require. Every data entry is logged with a timestamp and user identity. Modifications include reason-for-change documentation. Electronic signatures are 21 CFR Part 11–aligned for consent and data attestation. Role-based access ensures that only authorized personnel can enter, modify, or review data. And structured exports provide reproducible datasets that can be independently verified against the source system. This governance infrastructure is particularly important for RWD studies that will support post-marketing safety evaluations, label extension applications, or comparative effectiveness research. In these contexts, the data will be evaluated alongside traditional clinical trial data, and it must meet comparable standards of integrity and traceability.
RWD studies often operate under different timelines and funding structures than traditional clinical trials. Grant-funded academic studies may have fixed timelines tied to funding cycles. Post-marketing commitments may have regulatory deadlines. Health economics studies may be tied to product launch timelines or HTA submission windows. In all cases, the speed of EDC deployment matters. Capture supports rapid deployment for RWD studies through its browser-based configuration approach. Study teams build CRFs, configure visit schedules (or define event-driven data collection points), set up consent workflows, and create ePRO questionnaires without vendor development cycles. For studies that require validation, sandbox environments support UAT and testing before production deployment. Because RWD studies often evolve as data collection proceeds—new variables may need to be added, CRF fields refined, or follow-up schedules adjusted based on clinical patterns—Capture’s self-service amendment capability is particularly valuable. Study teams can make changes through the browser with audit trail documentation, without waiting for vendor turnaround.
Overview
Real-world data (RWD) refers to data relating to patient health status and healthcare delivery collected from sources outside traditional clinical trials. This includes data from electronic health records (EHRs), claims databases, disease registries, patient-reported outcomes, digital health devices, and other sources that reflect routine clinical practice. RWD studies systematically collect and analyze this data to answer clinical, epidemiological, and health services questions. The distinction between RWD and real-world evidence (RWE) is important: RWD is the raw data, while RWE is the clinical evidence derived from analyzing that data. The quality of RWE depends entirely on the quality of the underlying RWD—which means that how data is collected, managed, and governed during an RWD study directly determines whether the resulting evidence will be considered credible by regulators, payers, and the scientific community. For prospective RWD studies, your EDC must support flexible data capture that accommodates real-world care patterns, informed consent for study participation, optional ePRO for patient-reported data, and complete auditability for every data point. For retrospective RWD studies, the system must support structured data abstraction from source documents with clear attribution. For hybrid designs, both prospective and retrospective data capture must coexist within a single study. Capture provides EDC, eConsent, ePRO, and safety in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. The platform supports RWD collection from diverse sources within one system, maintaining the data integrity and traceability that downstream analysis and decision-making require.
RWD studies operate at the intersection of clinical research methodology and real-world healthcare delivery. This creates specific challenges for data capture that traditional trial-focused EDC platforms are not designed to handle. Visit schedules may be driven by clinical care rather than protocol-defined windows. Data may come from multiple sources—clinician assessments, patient self-report, medical record abstraction, and digital devices—within the same study. And the quality requirements for data intended to support regulatory or payer decisions are higher than for internal exploratory analyses. Legacy EDC systems impose structures designed for interventional trials: mandatory randomization fields, rigid visit windows, treatment-based data flows. These structures create operational friction in RWD studies, where the goal is to observe and record clinical reality rather than manage an experimental protocol. At the same time, using uncontrolled tools (spreadsheets, generic databases) for RWD collection creates data governance gaps that undermine the credibility of the resulting evidence. The challenge is particularly acute for prospective RWD studies designed to support regulatory or HTA submissions. The FDA and EMA have established clear expectations that such data be collected with quality controls, audit trails, and governance standards comparable to clinical trial data. An RWD study captured in a system without these controls may produce data that regulatory reviewers deem insufficient for decision-making—regardless of the study’s methodological rigor. Capture bridges this gap by providing flexible, study-type-agnostic data capture with the compliance infrastructure that regulatory and HTA use requires.
FAQ
Explore the platform with a free sandbox. No sales call required.